293 related articles for article (PubMed ID: 9666865)
21. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
Tyson D; Reggiardo D; Sklar C; David R
Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
[TBL] [Abstract][Full Text] [Related]
22. A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass.
Cheng JS; Salinas R; Molinaro A; Chang EF; Kunwar S; Blevins L; Aghi MK
J Clin Neurosci; 2015 Jan; 22(1):155-60. PubMed ID: 25481269
[TBL] [Abstract][Full Text] [Related]
23. The growth hormone, prolactin and TSH response to TRH and L-dopa in patients with hyperprolactinaemia and a normal-sized sella turcica may denote a pituitary adenoma.
Brismar K; Hulting AL; Werner S
J Intern Med; 1990 Nov; 228(5):435-42. PubMed ID: 2123920
[TBL] [Abstract][Full Text] [Related]
24. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
Colao A; Ferone D; Lombardi G; Lastoria S
Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
[TBL] [Abstract][Full Text] [Related]
25. Association Between Prolactinoma and Body Mass Index.
Al Sabie F; Tariq Z; Erickson D; Donegan D
Endocr Pract; 2021 Apr; 27(4):312-317. PubMed ID: 33720014
[TBL] [Abstract][Full Text] [Related]
26. [Hyperprolactinemia in patients with non-functioning adenoma: analysis of 85 patients treated by transsphenoidal operation].
Saitoh Y; Mori S; Arita N; Hayakawa T; Mogami H; Oku Y; Onishi T; Uozumi T
No Shinkei Geka; 1987 Nov; 15(11):1175-9. PubMed ID: 3437926
[TBL] [Abstract][Full Text] [Related]
27. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
Nachtigall LB; Valassi E; Lo J; McCarty D; Passeri J; Biller BM; Miller KK; Utz A; Grinspoon S; Lawson EA; Klibanski A
Clin Endocrinol (Oxf); 2010 Jan; 72(1):53-8. PubMed ID: 19508591
[TBL] [Abstract][Full Text] [Related]
28. GIANT PROLACTINOMA. A CASE REPORT.
Šulavíková Z; Krásnik V
Cesk Slov Oftalmol; 2023; 79(3):143-148. PubMed ID: 37344216
[TBL] [Abstract][Full Text] [Related]
29. [Reversible blindness caused by an invasive prolactinoma].
Schöfl-Siegert B; Brabant G; von zur Mühlen A; Schöfl C
Dtsch Med Wochenschr; 2001 May; 126(21):621-4. PubMed ID: 11413749
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
31. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
Lloyd HM; Jacobi JM; Willgoss DA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
[TBL] [Abstract][Full Text] [Related]
32. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
[TBL] [Abstract][Full Text] [Related]
33. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Schwetz V; Librizzi R; Trummer C; Theiler G; Stiegler C; Pieber TR; Obermayer-Pietsch B; Pilz S
Metab Brain Dis; 2017 Feb; 32(1):155-161. PubMed ID: 27525431
[TBL] [Abstract][Full Text] [Related]
34. Severe hyperprolactinemia associated with internal carotid artery aneurysm: differential diagnosis between prolactinoma and hypothalamic-pituitary disconnection.
Duarte FH; Machado MC; Lima JR; Salgado LR
Arq Bras Endocrinol Metabol; 2008 Oct; 52(7):1189-93. PubMed ID: 19082309
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and treatment of prolactinomas.
Molitch ME
Adv Intern Med; 1999; 44():117-53. PubMed ID: 9929707
[No Abstract] [Full Text] [Related]
36. Demographic characteristics, presentations and treatment outcome of patients with prolactinoma.
Malik S; Hussain SZ; Basit R; Idress N; Habib A; Zamant M; Islam N
J Ayub Med Coll Abbottabad; 2014; 26(3):269-74. PubMed ID: 25671924
[TBL] [Abstract][Full Text] [Related]
37. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1562-7. PubMed ID: 26256063
[TBL] [Abstract][Full Text] [Related]
38. Polycystic ovary syndrome and prolactinoma association.
Yavasoglu I; Kucuk M; Coskun A; Guney E; Kadikoylu G; Bolaman Z
Intern Med; 2009; 48(8):611-3. PubMed ID: 19367058
[TBL] [Abstract][Full Text] [Related]
39. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
[TBL] [Abstract][Full Text] [Related]
40. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies.
Badawy SZ; Marziale JC; Rosenbaum AE; Chang JK; Joy SE
Early Pregnancy; 1997 Dec; 3(4):306-11. PubMed ID: 10086082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
